NCT03621982 - Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

December 14, 2022

Study Completion Date

December 14, 2022

Conditions

Head and Neck Cancer Squamous Cell CarcinomaNon-small Cell Lung CancerGastric CancerEsophageal CancerPancreas CancerBladder CancerRenal Cell CarcinomaMelanomaTriple-negative Breast CancerOvarian CancerColo-rectal CancerFallopian Tube Cancer

Interventions

DRUG

ADCT-301

intravenous infusion

BIOLOGICAL

Pembrolizumab

intravenous infusion

Trial Locations (9)

9000

Universitair Ziekenhuis Gent, Ghent

37203

The Sarah Cannon Research Institute, Nashville

78229

The START Center for Cancer Care, San Antonio

94304

Stanford Cancer Center, Palo Alto

97239

Oregon Health and Science University, Portland

06511

Smilow Cancer Hospital Phase 1 Unit, New Haven

B-1070

Institut Jules Bordet, Anderlecht

NW1 2PG

University College London Hospitals NHS Foundation Trust, London

M20 4BX

The Christie NHS Foundation Trust, Manchester